Shutsung Liao
Research Subjects
Research Interests
Shutsung Liao has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
Richard A. Hiipakka
Ben May Department for Cancer Research
7 shared publicationsCatherine A. Reardon
Department of Pathology, University of Chicago, Chicago, IL, USA
4 shared publicationsJohn M. Kokontis
Ben May Department for Cancer Research
4 shared publicationsDacheng Peng
Ben May Department for Cancer Research, University of Chicago, Chicago, IL, USA
3 shared publicationsGodfrey S. Getz
Department of Pathology, University of Chicago, Chicago, IL, USA
3 shared publicationsChih-Pin Chuu
The Ben May Department for Cancer Research, The University of Chicago, CIS W325F, 929 E. 57th Street, Chicago, IL 60637, USA
2 shared publications
Latest Publications
- Open Access
- 14 January 2011
- Published by Wiley in British Journal of Pharmacology
- Vol. 162 (8) , 1792-1804
A novel potent synthetic steroidal liver X receptor agonist lowers plasma cholesterol and triglycerides and reduces atherosclerosis in LDLR–/– mice
BACKGROUND AND PURPOSE Potent synthetic nonsteroidal liver X receptor (LXR) agonists like T0901317 induce triglyceridaemia and fatty liver, effects not observed with some natural and synthetic steroidal, relatively weak agonists of LXR. To determine if potency is responsible for the lack of side effects with some steroidal agonists, we investigated the in vivo effects of a novel steroidal LXR agonist, ATI‐111, that is more potent than T0901317.EXPERIMENTAL APPROACH Eight week old male LDLR–/– mice fed an atherogenic diet were orally treated with vehicle or ATI‐111 at 3 and 5 mg·kg−1·day−1 for 8 weeks, and effects on plasma and liver lipid levels, expression of genes involved in lipid metabolism and on atherogenesis were analysed.KEY RESULTS ATI‐111 increased the expression of genes involved in lipid transport, such as ABCA1, ABCG1 and ABCG5/G8, in intestine and macrophages; decreased ABCG1, apoE; and slightly increased ABCA1 and ABCG5/G8 expression in liver. ATI‐111 markedly increased sterol regulatory element‐binding protein (SREBP)‐1c mRNA in some tissues, whereas acetyl‐coenzyme A carboxylase and fatty acid synthase expression was unaffected or only slightly increased in intestine and liver. ATI‐111 inhibited the conversion of SREBP‐1c precursor form to its active form. Compared with vehicle‐treated mice, the levels of hepatic lipids and liver‐secreted nascent lipoproteins were not altered, while a significant decrease in plasma cholesterol and triglyceride levels was observed in ATI‐111‐treated mice. ATI‐111 significantly inhibited atherogenesis in three separate vascular sites.CONCLUSIONS AND IMPLICATIONS ATI‐111 is a promising candidate for further development as a treatment of certain vascular diseases as it lacks the significant side effects associated with nonsteroidal LXR agonists, the induction of fatty liver and hypertriglyceridaemia.
- 14 January 2011
- Published by Wiley in British Journal of Pharmacology
- Vol. 162 (8) , 1792-1804
Open AccessA novel potent synthetic steroidal liver X receptor agonist lowers plasma cholesterol and triglycerides and reduces atherosclerosis in LDLR–/– mice
BACKGROUND AND PURPOSE Potent synthetic nonsteroidal liver X receptor (LXR) agonists like T0901317 induce triglyceridaemia and fatty liver, effects not observed with some natural and synthetic steroidal, relatively weak agonists of LXR. To determine if potency is responsible for the lack of side effects with some steroidal agonists, we investigated the in vivo effects of a novel steroidal LXR agonist, ATI‐111, that is more potent than T0901317.EXPERIMENTAL APPROACH Eight week old male LDLR–/– mice fed an atherogenic diet were orally treated with vehicle or ATI‐111 at 3 and 5 mg·kg−1·day−1 for 8 weeks, and effects on plasma and liver lipid levels, expression of genes involved in lipid metabolism and on atherogenesis were analysed.KEY RESULTS ATI‐111 increased the expression of genes involved in lipid transport, such as ABCA1, ABCG1 and ABCG5/G8, in intestine and macrophages; decreased ABCG1, apoE; and slightly increased ABCA1 and ABCG5/G8 expression in liver. ATI‐111 markedly increased sterol regulatory element‐binding protein (SREBP)‐1c mRNA in some tissues, whereas acetyl‐coenzyme A carboxylase and fatty acid synthase expression was unaffected or only slightly increased in intestine and liver. ATI‐111 inhibited the conversion of SREBP‐1c precursor form to its active form. Compared with vehicle‐treated mice, the levels of hepatic lipids and liver‐secreted nascent lipoproteins were not altered, while a significant decrease in plasma cholesterol and triglyceride levels was observed in ATI‐111‐treated mice. ATI‐111 significantly inhibited atherogenesis in three separate vascular sites.CONCLUSIONS AND IMPLICATIONS ATI‐111 is a promising candidate for further development as a treatment of certain vascular diseases as it lacks the significant side effects associated with nonsteroidal LXR agonists, the induction of fatty liver and hypertriglyceridaemia.
- 27 July 2009
- Published by Elsevier in Atherosclerosis
- Vol. 208 (1) , 126-133
Differential effects of activation of liver X receptor on plasma lipid homeostasis in wild-type and lipoprotein clearance-deficient mice
- 27 July 2009
- Published by Elsevier in Atherosclerosis
- Vol. 208 (1) , 126-133
Differential effects of activation of liver X receptor on plasma lipid homeostasis in wild-type and lipoprotein clearance-deficient mice
- 1 November 2008
- Published by Elsevier in The Journal of Pharmacology and Experimental Therapeutics
- Vol. 327 (2) , 332-342
Antiatherosclerotic Effects of a Novel Synthetic Tissue-Selective Steroidal Liver X Receptor Agonist in Low-Density Lipoprotein Receptor-Deficient Mice
Liver X receptor (LXR) agonists have the potential to treat atherosclerosis based on their ability to enhance reverse cholesterol transport. However, their side effects, such as induction of liver lipogenesis and triglyceridemia, may limit their pharmaceutical development. In contrast to the nonsteroidal LXR agonist N-(2,2,2-trifluoroethyl)-N-[4-[2,2,2-trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]phenyl]-benzenesulfonamide (T0901317), 3α, 6α, 24-trihydroxy-24, 24-di(trifluoromethyl)-5β-cholane (ATI-829), a novel potent synthetic steroidal LXR agonist, was a poor inducer of sterol regulatory element-binding protein 1c expression in hepatoma HepG2 cells, whereas both compounds increased ABCA1 expression in macrophage THP-1 cells. In male low-density lipoprotein receptor-deficient mice, ATI-829 selectively activated LXR target gene expression in mouse intestines and macrophages but not in the liver. A significant increase in liver triglyceride and plasma triglyceriderich small very low-density lipoprotein (VLDL) was observed in T0901317 but not ATI-829-treated mice. Compared with vehicle-treated mice, atherosclerosis development was significantly inhibited in the innominate artery after treatment with either compound. However, in the aortic root, inhibition of atherosclerosis was only observed in the right (right coronary artery-associated sinus) but not the left coronary-related sinus (left coronary artery-associated sinus; LC) of mice treated with either compound. Lesions in the innominate artery were less complex after treatment with either compound and contained mostly macrophage foam cells. In contrast, LC lesions were more complex and had a large collagen-positive fibrous cap and less macrophage foam cell area after treatment with either compound. The T0901317-induced hypertriglyceridemia was accompanied by an increase in small triglyceride-rich VLDL that may influence LXR agonist-mediated antiatherosclerotic effects at certain vascular sites. ATI-829, by selectively activating LXR in certain tissues without inducing hypertriglyceridemia, is a good candidate for drug development.
- 1 November 2008
- Published by Elsevier in The Journal of Pharmacology and Experimental Therapeutics
- Vol. 327 (2) , 332-342
Antiatherosclerotic Effects of a Novel Synthetic Tissue-Selective Steroidal Liver X Receptor Agonist in Low-Density Lipoprotein Receptor-Deficient Mice
Liver X receptor (LXR) agonists have the potential to treat atherosclerosis based on their ability to enhance reverse cholesterol transport. However, their side effects, such as induction of liver lipogenesis and triglyceridemia, may limit their pharmaceutical development. In contrast to the nonsteroidal LXR agonist N-(2,2,2-trifluoroethyl)-N-[4-[2,2,2-trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]phenyl]-benzenesulfonamide (T0901317), 3α, 6α, 24-trihydroxy-24, 24-di(trifluoromethyl)-5β-cholane (ATI-829), a novel potent synthetic steroidal LXR agonist, was a poor inducer of sterol regulatory element-binding protein 1c expression in hepatoma HepG2 cells, whereas both compounds increased ABCA1 expression in macrophage THP-1 cells. In male low-density lipoprotein receptor-deficient mice, ATI-829 selectively activated LXR target gene expression in mouse intestines and macrophages but not in the liver. A significant increase in liver triglyceride and plasma triglyceriderich small very low-density lipoprotein (VLDL) was observed in T0901317 but not ATI-829-treated mice. Compared with vehicle-treated mice, atherosclerosis development was significantly inhibited in the innominate artery after treatment with either compound. However, in the aortic root, inhibition of atherosclerosis was only observed in the right (right coronary artery-associated sinus) but not the left coronary-related sinus (left coronary artery-associated sinus; LC) of mice treated with either compound. Lesions in the innominate artery were less complex after treatment with either compound and contained mostly macrophage foam cells. In contrast, LC lesions were more complex and had a large collagen-positive fibrous cap and less macrophage foam cell area after treatment with either compound. The T0901317-induced hypertriglyceridemia was accompanied by an increase in small triglyceride-rich VLDL that may influence LXR agonist-mediated antiatherosclerotic effects at certain vascular sites. ATI-829, by selectively activating LXR in certain tissues without inducing hypertriglyceridemia, is a good candidate for drug development.
- 21 July 2008
- Published by Elsevier in Atherosclerosis
- Vol. 203 (1) , 59-66
Differential anti-atherosclerotic effects in the innominate artery and aortic sinus by the liver X receptor agonist T0901317
- 21 July 2008
- Published by Elsevier in Atherosclerosis
- Vol. 203 (1) , 59-66
Differential anti-atherosclerotic effects in the innominate artery and aortic sinus by the liver X receptor agonist T0901317
- 1 June 2007
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 357 (2) , 341-346
The liver X receptor agonist T0901317 acts as androgen receptor antagonist in human prostate cancer cells
- 1 June 2007
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 357 (2) , 341-346
The liver X receptor agonist T0901317 acts as androgen receptor antagonist in human prostate cancer cells
- 20 March 2007
- Published by Springer Nature in Journal of Biomedical Science
- Vol. 14 (5) , 543-553
Modulation of liver X receptor signaling as novel therapy for prostate cancer
Liver X receptors (LXRs) are important regulators of cholesterol, fatty acid, and glucose homeostasis. LXR agonists are effective for treatment of murine models of atherosclerosis, diabetes, and Alzheimer’s disease. Recently we observed that LXR agonists suppressed proliferation of prostate and breast cancer cells in vitro and treatment of mice with the LXR agonist T0901317 suppressed the growth of prostate tumor xenografts. LXR agonists appear to cause G1 cell cycle arrest in cells by reducing expression of Skp2 and inducing the accumulation of p27Kip. T0901317 induced expression of ATP-binding cassette transporter A1 (ABCA1) and delayed the progression of androgen-dependent human prostate tumor xenografts towards androgen-independency in mice. Phytosterols, the plant equivalent of mammalian cholesterol, have recently been shown to be agonists for LXRs. β-Sitosterol and campesterol, the two most common phytosterols, suppressed proliferation of prostate and breast cancer cells. The anticancer activity of phytosterols may be due to LXR signaling. This review examines the potential use of LXR signaling as a therapeutic target in prostate and other cancers.
- 20 March 2007
- Published by Springer Nature in Journal of Biomedical Science
- Vol. 14 (5) , 543-553
Modulation of liver X receptor signaling as novel therapy for prostate cancer
Liver X receptors (LXRs) are important regulators of cholesterol, fatty acid, and glucose homeostasis. LXR agonists are effective for treatment of murine models of atherosclerosis, diabetes, and Alzheimer’s disease. Recently we observed that LXR agonists suppressed proliferation of prostate and breast cancer cells in vitro and treatment of mice with the LXR agonist T0901317 suppressed the growth of prostate tumor xenografts. LXR agonists appear to cause G1 cell cycle arrest in cells by reducing expression of Skp2 and inducing the accumulation of p27Kip. T0901317 induced expression of ATP-binding cassette transporter A1 (ABCA1) and delayed the progression of androgen-dependent human prostate tumor xenografts towards androgen-independency in mice. Phytosterols, the plant equivalent of mammalian cholesterol, have recently been shown to be agonists for LXRs. β-Sitosterol and campesterol, the two most common phytosterols, suppressed proliferation of prostate and breast cancer cells. The anticancer activity of phytosterols may be due to LXR signaling. This review examines the potential use of LXR signaling as a therapeutic target in prostate and other cancers.